HDL function and cardiovascular risk: Debate continues...

Atherosclerosis

Volumn 229, Issue 1, 2013, Pages 38-41

  Stock, Jane ^a  

^a not available   (Sweden)

Author keywords

Animal models; Atheroprotective effects; Cardiovascular risk; Cholesterol; Chronic kidney disease; Debate; Dyslipidaemia management; HDL cholesterol; HDL function; High density lipoprotein; Lipid laden macrophages; Low density lipoprotein

Indexed keywords

CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LIFESTYLE; LIPID ANALYSIS; MEASUREMENT; META ANALYSIS (TOPIC); NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION;

EID: 84879418430     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.04.032     Document Type: Note

References (24)

1. Catapano A.L., Reiner Z., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Atherosclerosis 2011, 217:3-46.
2. Khera A.V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. NEngl J Med 2011, 364:127-135.
3. Li X.-M., Tang W.H.W., Mosior M.K., et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risk. Arterioscler Thromb Vasc Biol 2013, [Epub ahead of print].
4. Asztalos B.F., Cupples L.A., Demissie S., et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004, 24:2181-2187.
5. Favari E., Lee M., Calabresi L., et al. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1-but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. JBiol Chem 2004, 279:9930-9936.
6. de la Llera-Moya M., Drazul-Schrader D., Asztalos B.F., et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010, 30:796-801.
7. Kane J.P., Malloy M.J. Prebeta-1 HDL and coronary heart disease. Curr Opin Lipidol 2012, 23:367-371.
8. Baigent C., Burbury K., Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000, 356:147-152.
9. Palmer S.C., Craig J.C., Navaneethan S.D., et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and analysis. Ann Intern Med 2012, 157:263-275.
10. Upadhyay A., Earley A., Lamont J.L., et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012, 157:251-262.
11. Liu Y., Coresh J., Eustace J.A., et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004, 291:451-459.
12. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192.
13. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. NEngl J Med 2009, 360:1395-1407.
14. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2diabetes mellitus undergoing hemodialysis. NEngl J Med 2005, 353:238-248.
15. Hou W., Lv J., Perkovic V., et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart March 6, 2013, [Epub ahead of print].
16. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
17. Wilkins J.T., Ning H., Berry J., Zhao L., Dyer A.R., Lloyd-Jones D.M. Lifetime riskand years lived free of total cardiovascular disease. JAMA 2012, 308:1795-1801.
18. Estruch R., Ros E., Salas-Salvado J. PREDIMED Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. NEngl J Med 25 February, 2013, [Epub ahead of print].
19. Bendinelli B., Masala G., Saieva C., et al. Fruit, vegetables, and olive oil and risk of coronary heart disease in Italian women: the EPICOR Study. Am J Clin Nutr 2011, 93:275-283.
20. Samieri C., Féart C., Proust-Lima C., et al. Olive oil consumption, plasma oleic acid, and stroke incidence: the Three-City Study. Neurology 2011, 77:418-425.
21. Ros E., Tapsell L.C., Sabaté J. Nuts and berries for heart health. Curr Atheroscler Rep 2010, 12:397-406.
22. Mitjavila M.T., Eandos M., Salas-Salvado J., et al. The Mediterranean diet improves systemic lipid and DNA oxidative damage in metabolic syndrome individuals. A randomized, controlled, trial. Clin Nutr 2013, 32:172-178.
23. Taylor F., Huffman M.D., Macedo A.F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013, (1). Art. No.: CD004816. 10.1002/14651858.CD004816.pub5.
24. Iacoviello L., Bonanni A., Costanzo S., et al. The Moli-sani project, a randomized, prospective cohort study in the Molise region in Italy; design, rationale and objectives. Italian J Public Health 2007, 10.2427/5886.